Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from JNJ

3 Dividend Aristocrats With Consistent Payouts

Investing in dividend aristocrats can form the cornerstone of a reliable investment strategy, owing to their qualities like consistent payouts, recession-proof, and risk protection. So, it could be wise to invest in dividend aristocrat stocks Johnson & Johnson (JNJ), PepsiCo (PEP), and Target (TGT) for substantial gains. Keep reading….

StockNews.com

Johnson & Johnson Stock Outlook: Is Wall Street Bullish or Bearish?

Despite Johnson & Johnson's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.

Barchart

3 Dividend Growth Stocks Perfect for Long-Term Investors

Dividend growth stocks offer a balance of stability and compounding returns, and here are three standout companies with strong financials, consistent dividend increases, and long-term growth potential: Johnson & Johnson (JNJ), PepsiCo (PEP), and Target (TGT). Read on.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Dividend Kings You Should Snap Up Immediately

Recent earnings from these dividend-paying companies reflects their stability.

Barchart

Abbott Laboratories Will Outperform Healthcare Stocks in 2025

Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026.

MarketBeat

MarketBeat Week in Review – 01/13 - 01/17

The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally

MarketBeat

Is Johnson & Johnson Stock Set to Reward Long-Term Holders?

JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive

MarketBeat

Read news from The Economist, FT, and more,
with one subscription

3 Pharmaceutical Stocks Addressing Global Health Challenges

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to pioneering global healthcare solutions. Hence, investing in established pharmaceutical stocks, Pfizer (PFE), Johnson & Johnson (JNJ), and Merck & Co. (MRK) presents a compelling opportunity to capitalize for the long term. Read more.

StockNews.com

3 Blue-Chip Stocks with Strong Buy Ratings from Analysts

As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability and long-term growth potential. Thus, one could consider adding these three fundamentally sound blue-chip stocks, AbbVie (ABBV), Merck & Co. (MRK), and Johnson & Johnson (JNJ), with Strong Buy ratings from…

StockNews.com

Top 3 Discounted Dividend Stocks for 2025 That Could Skyrocket Your Portfolio

These three companies are leaders in their field, have a long history of increasing their dividends, and the stocks trade at a discount.

Barchart

3 Dividend Aristocrats Every Investor Should Own

Dividend Aristocrats are a shield during market turbulence and a key to diversified growth. Therefore, investors looking for stability and dependable income might consider adding fundamentally stable stocks Johnson & Johnson (JNJ), PepsiCo (PEP), and Kimberly-Clark (KMB). Continue reading….

StockNews.com

Johnson & Johnson's Quarterly Earnings Preview: What You Need to Know

Johnson & Johnson is poised to release its fiscal fourth-quarter earnings this month, and analysts project a double-digit profit decline.

Barchart

Bearish Screener Results: Bear Call Spread Opportunities for December 19th

Let’s take a look at Barchart’s Bear Call Spread Screener for December 19th:

Barchart

3 Healthcare Innovators Revolutionizing Patient Care

The healthcare sector is transforming with the adoption of digital technologies, improved productivity, and increasing R&D efforts. Thus, investors could consider quality healthcare innovator stocks Johnson & Johnson (JNJ), Merck & Co (MRK), and Bristol-Myers Squibb (BMY) as portfolio additions for potential gains. Continue reading.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Healthcare ETFs for a Balanced Investment Approach

For investors seeking a balanced approach, healthcare ETFs offer a combination of stability and growth potential. Therefore, it might be wise to consider Fidelity MSCI Health Care Index ETF (FHLC), iShares U.S. Healthcare ETF (IYH), and Vanguard Health Care Index Fund ETF Shares (VHT) for a balanced approach. Keep reading….

Barchart

Is Johnson & Johnson Stock Underperforming the Nasdaq?

Johnson & Johnson has underperformed the Nasdaq over the past year, but analysts are moderately optimistic about the stock’s prospects.

StockNews.com

3 Blue-Chip Stocks to Anchor Your Portfolio

Amid ongoing uncertainties surrounding the economy and global power dynamics, market volatility continues to dominate. In such times, investing in fundamentally sound blue-chip stocks, Johnson & Johnson (JNJ), American Express (AXP), and AT&T (T), could offer investors a stable foundation, serving as a buffer against market fluctuations and uncertainty. Read…

StockNews.com

Top 3 Dividend Aristocrats to Add to Your Portfolio

Dividend Aristocrats offer stability, reliable income, and risk mitigation, with consistent dividend growth helping to combat uncertain times. Hence, it could be wise to add top Dividend Aristocrats like Johnson & Johnson (JNJ), PepsiCo (PEP), and Kimberly-Clark (KMB) to your portfolio. Read on.

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Dividend Growth Stocks to Secure for Long-Term Wealth

During market volatility and economic downturns, investors often turn to stocks offering stable dividends and growth opportunities. Thus, quality dividend stocks Johnson & Johnson (JNJ), Lowe's Companies (LOW), and Target Corporation (TGT) could be ideal portfolio additions for long-term wealth. Continue reading.

Barchart

Are Wall Street Analysts Predicting Johnson & Johnson Stock Will Climb or Sink?

Johnson & Johnson has struggled to keep up with the broader market over the past year, and analysts are cautiously bullish on its future potential.

StockNews.com

3 Defensive Stocks to Buy as Market Volatility Rises

Amid current economic uncertainties and market volatility, investing in defensive stocks appears as an ideal strategy for portfolio protection. Thus, quality defensive stocks Johnson & Johnson (JNJ), Pfizer (PFE), and Genie Energy (GNE) could be ideal portfolio additions as market volatility rises. Continue reading.

StockNews.com

3 Healthcare Stocks for Long-Term Stability and Growth

With the rise of chronic diseases, technological advances and innovative drug pipelines are driving significant growth in the healthcare industry. Hence, investors may find long-term stability and exciting opportunities by adding stocks, Johnson & Johnson (JNJ), Pfizer (PFE), and Cigna Group (CI), to their portfolios. Read more….

StockNews.com

3 Dividend Stocks With 3% or More Yields to Watch Now

Dividend stocks are a top choice for long-term investors, with dependable payout and steady performance. Therefore, it could be wise to keep track of top dividend stocks, such as Johnson & Johnson (JNJ), Northwest Natural Holding Co. (NWN), and Universal Corp (UVV). Read more….

StockNews.com

3 Healthcare Stocks for Safe, Steady Growth

The healthcare industry is set for growth due to the growing demand for quality healthcare services and ongoing advancements in medical technology. Hence, investors might consider investing in healthcare stocks, Johnson & Johnson (JNJ), AbbVie (ABBV), and Thermo Fisher Scientific (TMO) for safe and steady growth. Read more….

Barchart

Johnson & Johnson's Q3 2024 Earnings: What to Expect

Johnson & Johnson is all set to announce its third-quarter results this month, and analysts are projecting double-digit earnings decline.

1 … 4 5 6 7

People

Gabriel OsorioMazilli

50 stories

Jea Yu

23 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.